The Journal of dermatological treatment · 2025
Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study.
СтатьяМногоцентровое исследованиеРандомизированное исследованиеКлиническое исследование II фазыНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hu Ruiming, Wei Aihua, Wu Liming, Yang Bin, Li Ji, Li Linfeng, Zhao Yi, Yang Chunjun, Zhang Guoqiang, Li Yumei, Wan Jianji, Wang Huiping, Wang Meiyu, Ni Xiang, Tong Youzhi, Yang Qinping
Аннотация
BACKGROUND: Androgenetic alopecia (AGA) is a common, age-related, androgen-dependent condition. Dihydrotestosterone and androgen receptors play key roles in its pathogenesis.
METHODS: This multicenter, randomized, double-blind, placebo-controlled Phase II trial evaluated the efficacy and safety of topical GT20029 in Chinese adult males with AGA. From April 2023 to April 2024, 180 eligible subjects (Hamilton-Norwood IIIv-V) were randomized equally into six groups receiving GT20029 (0.5% or 1.0%) or placebo, either once daily (QD) or twice weekly (BIW) for 12 weeks. The primary endpoint was the change in target area non-vellus hair count (TAHC) at Week 12; secondary endpoints included TAHC at Week 6, hair width (TAHW), and terminal/vellus hair ratio. Safety was assessed via adverse events (AEs).
RESULTS: All four GT20029-treated groups showed significant increases in TAHC at Week 12 (p < 0.001), with 0.5% QD and 1.0% BIW groups showing significant improvement over their respective placebo groups (p = 0.032 and p = 0.023). TAHW also improved significantly in the 1.0% BIW group vs placebo (p = 0.011). TEAE incidence was similar across all groups and mostly mild.
CONCLUSION: Topical GT20029 demonstrated significant efficacy in hair regrowth with good tolerability. Further studies are warranted to confirm its therapeutic potential in AGA.
METHODS: This multicenter, randomized, double-blind, placebo-controlled Phase II trial evaluated the efficacy and safety of topical GT20029 in Chinese adult males with AGA. From April 2023 to April 2024, 180 eligible subjects (Hamilton-Norwood IIIv-V) were randomized equally into six groups receiving GT20029 (0.5% or 1.0%) or placebo, either once daily (QD) or twice weekly (BIW) for 12 weeks. The primary endpoint was the change in target area non-vellus hair count (TAHC) at Week 12; secondary endpoints included TAHC at Week 6, hair width (TAHW), and terminal/vellus hair ratio. Safety was assessed via adverse events (AEs).
RESULTS: All four GT20029-treated groups showed significant increases in TAHC at Week 12 (p < 0.001), with 0.5% QD and 1.0% BIW groups showing significant improvement over their respective placebo groups (p = 0.032 and p = 0.023). TAHW also improved significantly in the 1.0% BIW group vs placebo (p = 0.011). TEAE incidence was similar across all groups and mostly mild.
CONCLUSION: Topical GT20029 demonstrated significant efficacy in hair regrowth with good tolerability. Further studies are warranted to confirm its therapeutic potential in AGA.